文献速递临床试验与 GCP

术中麻醉交接对成人死亡率、再入院或术后并发症的影响:HandiCAP随机临床试验

Effect of Intraoperative Handovers of Anesthesia Care on Mortality, Readmission, or Postoperative Complications Among Adults: The HandiCAP Randomized Clinical Trial.
PubMed 文献 · JAMA · 2022-01-01

这项在德国12个中心开展的平行组随机临床试验纳入1817例美国麻醉医师学会体能状态3或4级、拟行预计至少2小时的大手术成人患者,比较麻醉交接(n=908)与无交接(n=909)对30天全因死亡、再入院或严重术后并发症复合结局的影响。结果显示两组复合主要结局无显著差异(30% vs 33%;RD -2.5%,95%CI -6.8%至1.9%;OR 0.89,95%CI 0.72至1.10;P=0.27),19项预设次要终点均无显著差异。

要点

  • 麻醉交接组与无交接组30天复合主要结局无显著差异(30% vs 33%;OR 0.89,95%CI 0.72至1.10;P=0.27)。
  • 30天全因死亡:交接组2.1% vs 无交接组3.4%(OR 0.61,95%CI 0.34至1.10;P=0.11),无显著差异。
  • 再入院13% vs 16%(OR 0.80,95%CI 0.61至1.05;P=0.12)、严重术后并发症22% vs 22%(OR 1.02,95%CI 0.81至1.28;P=0.91)均无显著差异。

核心结论

  • 在接受较长时间手术的成人中,麻醉交接组与无交接组在30天死亡、再入院或严重术后并发症复合主要结局上无显著差异。

研究设计与样本

  • 平行组随机临床试验,在德国12个中心开展,2019年6月至2021年6月入组,最终随访至2021年7月31日。
  • 纳入美国麻醉医师学会体能状态3或4级、拟行预计至少2小时的大手术住院患者,共1817例随机分组:麻醉交接组908例,无交接组909例。
  • 参与机构均未使用标准化交接方案;1772例(98%)完成试验,平均年龄66岁(SD 12),男性997例(56%),美国麻醉医师学会体能状态3级1717例(97%)。

主要发现

  • 复合主要结局:交接组891例中268例(30%) vs 无交接组881例中284例(33%)(绝对风险差-2.5%,95%CI -6.8%至1.9%;OR 0.89,95%CI 0.72至1.10;P=0.27)。
  • 30天全因死亡:交接组889例中19例(2.1%) vs 无交接组873例中30例(3.4%)(绝对风险差-1.3%,95%CI -2.8%至0.2%;OR 0.61,95%CI 0.34至1.10;P=0.11)。
  • 再入院:交接组888例中115例(13%) vs 无交接组872例中136例(16%)(绝对风险差-2.7%,95%CI -5.9%至0.6%;OR 0.80,95%CI 0.61至1.05;P=0.12)。
  • 严重术后并发症:交接组890例中195例(22%) vs 无交接组874例中189例(22%)(绝对风险差0.3%,95%CI -3.6%至4.1%;OR 1.02,95%CI 0.81至1.28;P=0.91)。
  • 19项预设次要终点均无显著差异;麻醉总时间中位数267分钟(IQR 206-351分钟),交接组从麻醉开始至首次交接时间中位数144分钟(IQR 105-213分钟)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Intraoperative handovers of anesthesia care are common. Handovers might improve care by reducing physician fatigue, but there is also an inherent risk of losing critical information. Large observational analyses report associations between handover of anesthesia care and adverse events, including higher mortality. OBJECTIVE: To determine the effect of handovers of anesthesia care on postoperative morbidity and mortality. DESIGN, SETTING, AND PARTICIPANTS: This was a parallel-group, randomized clinical trial conducted in 12 German centers with patients enrolled between June 2019 and June 2021 (final follow-up, July 31, 2021). Eligible participants had an American Society of Anesthesiologists physical status 3 or 4 and were scheduled for major inpatient surgery expected to last at least 2 hours. INTERVENTIONS: A total of 1817 participants were randomized to receive either a complete handover to receive anesthesia care by another clinician (n = 908) or no handover of anesthesia care (n = 909). None of the participating institutions used a standardized handover protocol. MAIN OUTCOMES AND MEASURES: The primary outcome was a 30-day composite of all-cause mortality, hospital readmission, or serious postoperative complications. There were 19 secondary outcomes, including the components of the primary composite, along with intensive care unit and hospital lengths of stay. RESULTS: Among 1817 randomized patients, 1772 (98%; mean age, 66 [SD, 12] years; 997 men [56%]; and 1717 [97%] with an American Society of Anesthesiologists physical status of 3) completed the trial. The median total duration of anesthesia was 267 minutes (IQR, 206-351 minutes), and the median time from start of anesthesia to first handover was 144 minutes in the handover group (IQR, 105-213 minutes). The composite primary outcome occurred in 268 of 891 patients (30%) in the handover group and in 284 of 881 (33%) in the no handover group (absolute risk difference [RD], -2.5%; 95% CI, -6.8% to 1.9%; odds ratio [OR], 0.89; 95% CI, 0.72 to 1.10; P = .27). Nineteen of 889 patients (2.1%) in the handover group and 30 of 873 (3.4%) in the no handover group experienced all-cause 30-day mortality (absolute RD, -1.3%; 95% CI, -2.8% to 0.2%; OR, 0.61; 95% CI, 0.34 to 1.10; P = .11); 115 of 888 (13%) vs 136 of 872 (16%) were readmitted to the hospital (absolute RD, -2.7%; 95% CI, -5.9% to 0.6%; OR, 0.80; 95% CI, 0.61 to 1.05; P = .12); and 195 of 890 (22%) vs 189 of 874 (22%) experienced serious postoperative complications (absolute RD, 0.3%; 95% CI, -3.6% to 4.1%; odds ratio, 1.02; 95% CI, 0.81 to 1.28; P = .91). None of the 19 prespecified secondary end points differed significantly. CONCLUSIONS AND RELEVANCE: Among adults undergoing extended surgical procedures, there was no significant difference between the patients randomized to receive handover of anesthesia care from one clinician to another, compared with the no handover group, in the composite primary outcome of mortality, readmission, or serious postoperative complications within 30 days. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04016454.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Meersch M, Weiss R, Küllmar M, et al. Effect of Intraoperative Handovers of Anesthesia Care on Mortality, Readmission, or Postoperative Complications Among Adults: The HandiCAP Randomized Clinical Trial. JAMA. 2022. PMID: 35665794. doi:10.1001/jama.2022.9451

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。